Steven C. Gilman - 10 Jun 2025 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Reporting relationship: Director
Issuer ticker: AKBA
Reported as of: 10 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Jun 2025, 17:14:24 UTC
Prior SEC filing: 18 Oct 2024
Next SEC filing: 30 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Carolyn Rucci, attorney-in-fact for Steven C. Gilman

Key filing fact

Steven C. Gilman filed Form 4 for Akebia Therapeutics, Inc. (AKBA) on 11 Jun 2025.

Key facts

This page summarizes Steven C. Gilman's Form 4 filing for Akebia Therapeutics, Inc. (AKBA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 11 Jun 2025, 17:14.

Change

Previous filing in this sequence was filed on 18 Oct 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001379970 Primary reporting owner

GILMAN STEVEN C

Relationship: Director
Address: C/O AKEBIA THERAPEUTICS, INC., 245 FIRST ST., CAMBRIDGE
Signature: /s/ Carolyn Rucci, attorney-in-fact for Steven C. Gilman
Signature date: 11 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AKBA transaction

Common Stock

Award

Transaction value: $0
Shares: +35,700
Change %: +30%
Price: $0.000000
Shares after: 152,830
Date: 10 Jun 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AKBA transaction Derivative

Stock Option (Right to buy)

Award

Transaction value: $0
Shares: +53,600
Change %
Price: $0.000000
Shares after: 53,600
Date: 10 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 53,600
Exercise price: $3.92
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer.

Footnote F2

The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer.